JP2017513892A5 - - Google Patents

Download PDF

Info

Publication number
JP2017513892A5
JP2017513892A5 JP2016564087A JP2016564087A JP2017513892A5 JP 2017513892 A5 JP2017513892 A5 JP 2017513892A5 JP 2016564087 A JP2016564087 A JP 2016564087A JP 2016564087 A JP2016564087 A JP 2016564087A JP 2017513892 A5 JP2017513892 A5 JP 2017513892A5
Authority
JP
Japan
Prior art keywords
methyl
hydroxy
methylsulfonyl
propanamide
dihydroisoxazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016564087A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017513892A (ja
JP6514716B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/027009 external-priority patent/WO2015164458A1/en
Publication of JP2017513892A publication Critical patent/JP2017513892A/ja
Publication of JP2017513892A5 publication Critical patent/JP2017513892A5/ja
Application granted granted Critical
Publication of JP6514716B2 publication Critical patent/JP6514716B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016564087A 2014-04-22 2015-04-22 LpxC阻害剤としてのイソオキサゾリンヒドロキサム酸誘導体 Expired - Fee Related JP6514716B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461982467P 2014-04-22 2014-04-22
US61/982,467 2014-04-22
PCT/US2015/027009 WO2015164458A1 (en) 2014-04-22 2015-04-22 Isoxazoline hydroxamic acid derivatives as lpxc inhibitors

Publications (3)

Publication Number Publication Date
JP2017513892A JP2017513892A (ja) 2017-06-01
JP2017513892A5 true JP2017513892A5 (https=) 2018-05-24
JP6514716B2 JP6514716B2 (ja) 2019-05-15

Family

ID=53059459

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016564087A Expired - Fee Related JP6514716B2 (ja) 2014-04-22 2015-04-22 LpxC阻害剤としてのイソオキサゾリンヒドロキサム酸誘導体

Country Status (6)

Country Link
US (2) US9637482B2 (https=)
EP (1) EP3134401B1 (https=)
JP (1) JP6514716B2 (https=)
CN (1) CN106573924B (https=)
ES (1) ES2687393T3 (https=)
WO (1) WO2015164458A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3386950A1 (en) * 2015-12-08 2018-10-17 GlaxoSmithKline Intellectual Property Development Limited Substituted benzazinones as antibacterial compounds
JP6941630B2 (ja) * 2016-06-14 2021-09-29 ノバルティス アーゲー 抗菌剤としての(r)−4(5−(シクロプロピルエチニル)イソオキサゾール−3−イル)−n−ヒドロキシ−2−メチル−2−(メチルスルホニル)ブタンアミドの結晶形
JP6812542B2 (ja) * 2016-09-28 2021-01-13 ドン−ア エスティ カンパニー リミテッド テトラヒドロピリジン誘導体および抗菌剤としてのその使用
KR20210093884A (ko) * 2018-11-21 2021-07-28 다이쇼 세이야꾸 가부시끼가이샤 신규 이미다졸 유도체
WO2020142764A1 (en) * 2019-01-06 2020-07-09 Psomagen Inc. Htra inhibitors and caga inhibitors and use thereof
CN119816496A (zh) * 2022-09-28 2025-04-11 浙江海正药业股份有限公司 芳香乙炔类衍生物及其制备方法和用途
WO2024153173A1 (zh) * 2023-01-19 2024-07-25 浙江海正药业股份有限公司 芳香乙炔类衍生物及其制备方法和用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1046274C (zh) * 1993-11-26 1999-11-10 辉瑞大药厂 用作消炎剂的异噁唑啉化合物
US7125870B2 (en) * 2002-11-06 2006-10-24 Bristol-Myers Squibb Company Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme
KR101076018B1 (ko) 2003-01-08 2011-10-21 유니버시티 오브 워싱톤 항균제
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
JP5524215B2 (ja) 2008-09-19 2014-06-18 ファイザー・インク 抗菌剤として有用なヒドロキサム酸誘導体
WO2011045703A2 (en) * 2009-10-13 2011-04-21 Pfizer Inc. C-linked hydroxamic acid derivatives useful as antibacterial agents
WO2011073845A1 (en) 2009-12-16 2011-06-23 Pfizer Inc. N-linked hydroxamic acid derivatives useful as antibacterial agents
ES2626457T3 (es) 2011-03-07 2017-07-25 Pfizer Inc. Derivados de fluoro-piridinona útiles como agentes antibacterianos
ES2526687T3 (es) 2011-04-08 2015-01-14 Pfizer Inc. Derivados de isoxazol útiles como agentes antibacterianos
KR20120137094A (ko) * 2011-06-10 2012-12-20 현대자동차주식회사 차량용 소음기
WO2014160649A1 (en) 2013-03-29 2014-10-02 Novartis Ag Hydroxamic acid derivatives as lpxc inhibitors for the treatment of bacterial infections

Similar Documents

Publication Publication Date Title
JP2017513892A5 (https=)
HRP20192009T1 (hr) Spojevi izoksazol hidroksamske kiseline kao inhibitori lpxc-a
ES2535244T3 (es) Compuestos heterocíclicos adecuados para el tratamiento de dislipidemia
RU2016117941A (ru) Фениколовые противобактериальные средства
RU2019121871A (ru) Новые производные фенилпропионовой кислоты и их применение
JP2020502111A5 (https=)
JP2012502946A5 (https=)
JP2019517455A5 (https=)
JP2013521286A5 (https=)
IL264982B (en) Hetero(aryl)cyclopropylamine compounds as lsd1 inhibitors
JP2007525516A5 (https=)
HRP20161011T1 (hr) Aril dihidropiridinoni i piperidinoni kao inhibitori mgat2
HRP20170422T1 (hr) 3-(2-aril-cikloalkenilmetil)-oksazolidin-2-on derivati kao inhibitori transportnog proteina estera kolesterola (cetp)
JP2010516715A5 (https=)
PE20220711A1 (es) Derivados de 2-isoindol-1,3,4-oxadiazol utiles como inhibidores de la histona desacetilasa 6 (hdac6)
IL273000B2 (en) Compounds that inhibit lysophosphatidic acid receptor 1 (lpar1)
JP2015536974A5 (https=)
JP2021515004A5 (https=)
HRP20190668T1 (hr) Tetrazolonom supstituirani dihidropiridinonski mgat2 inhibitori
JP2017505293A5 (https=)
CA2564990A1 (en) Morpholine compounds
RU2012142171A (ru) Ингибиторы катехол-о-метилтрансферазы и их применение в лечении психических расстройств
RU2015116540A (ru) Замещенные соединения спиропиперидинила, применяемые в качестве агонистов gpr120
RU2011104223A (ru) Азотсодержащее ароматическое гетероциклическое соединение
JP2013521288A5 (https=)